Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

Jun Soo Kwon, Sung Nyun Kim, Jaewook Han, Sang Ick Lee, Jae Seung Chang, Jung Seok Choi, Heon-Jeong Lee, Seong Jin Cho, Tae Youn Jun, Seung Hwan Lee, Changsu Han, Kyoung Uk Lee, Kyung Kyu Lee, Eunjung Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.

Original languageEnglish
Pages (from-to)320-328
Number of pages9
JournalInternational Clinical Psychopharmacology
Volume30
Issue number6
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Antipsychotic Agents
Patient Satisfaction
Schizophrenia
Therapeutics
Injections
Paliperidone Palmitate
Surveys and Questionnaires

Keywords

  • Atypical antipsychotics
  • Long-acting injectable antipsychotics
  • Medication Satisfaction Questionnaire
  • Paliperidone palmitate
  • Schizophrenia
  • Treatment Satisfaction Questionnaire for Medication

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. / Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; Lee, Sang Ick; Chang, Jae Seung; Choi, Jung Seok; Lee, Heon-Jeong; Cho, Seong Jin; Jun, Tae Youn; Lee, Seung Hwan; Han, Changsu; Lee, Kyoung Uk; Lee, Kyung Kyu; Lee, Eunjung.

In: International Clinical Psychopharmacology, Vol. 30, No. 6, 01.10.2015, p. 320-328.

Research output: Contribution to journalArticle

Kwon, Jun Soo ; Kim, Sung Nyun ; Han, Jaewook ; Lee, Sang Ick ; Chang, Jae Seung ; Choi, Jung Seok ; Lee, Heon-Jeong ; Cho, Seong Jin ; Jun, Tae Youn ; Lee, Seung Hwan ; Han, Changsu ; Lee, Kyoung Uk ; Lee, Kyung Kyu ; Lee, Eunjung. / Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. In: International Clinical Psychopharmacology. 2015 ; Vol. 30, No. 6. pp. 320-328.
@article{ecc182d08b9e4ece99c38d0db061d356,
title = "Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics",
abstract = "Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.",
keywords = "Atypical antipsychotics, Long-acting injectable antipsychotics, Medication Satisfaction Questionnaire, Paliperidone palmitate, Schizophrenia, Treatment Satisfaction Questionnaire for Medication",
author = "Kwon, {Jun Soo} and Kim, {Sung Nyun} and Jaewook Han and Lee, {Sang Ick} and Chang, {Jae Seung} and Choi, {Jung Seok} and Heon-Jeong Lee and Cho, {Seong Jin} and Jun, {Tae Youn} and Lee, {Seung Hwan} and Changsu Han and Lee, {Kyoung Uk} and Lee, {Kyung Kyu} and Eunjung Lee",
year = "2015",
month = "10",
day = "1",
doi = "10.1097/YIC.0000000000000093",
language = "English",
volume = "30",
pages = "320--328",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

AU - Kwon, Jun Soo

AU - Kim, Sung Nyun

AU - Han, Jaewook

AU - Lee, Sang Ick

AU - Chang, Jae Seung

AU - Choi, Jung Seok

AU - Lee, Heon-Jeong

AU - Cho, Seong Jin

AU - Jun, Tae Youn

AU - Lee, Seung Hwan

AU - Han, Changsu

AU - Lee, Kyoung Uk

AU - Lee, Kyung Kyu

AU - Lee, Eunjung

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.

AB - Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.

KW - Atypical antipsychotics

KW - Long-acting injectable antipsychotics

KW - Medication Satisfaction Questionnaire

KW - Paliperidone palmitate

KW - Schizophrenia

KW - Treatment Satisfaction Questionnaire for Medication

UR - http://www.scopus.com/inward/record.url?scp=84942750247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942750247&partnerID=8YFLogxK

U2 - 10.1097/YIC.0000000000000093

DO - 10.1097/YIC.0000000000000093

M3 - Article

C2 - 26196188

AN - SCOPUS:84942750247

VL - 30

SP - 320

EP - 328

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -